SEC Form 4 · accession 0001601830-26-000091
RECURSION PHARMACEUTICALS, INC. · RXRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dean Y Li
Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 5:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001601830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Jul 1, 2026 | A | 3,747 | $0.00 | A | 1,473,329 | D | |
| Class A Common Stock | holding | — | — | — | 1,422,048 | I | By Dean Y. Li Revocable Trust | |
| Class A Common Stock | holding | — | — | — | 421,000 | I | By Dean Y. Li 2021 Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.